Neurogene Inc.
NGNE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404644
In the last 90 days, Neurogene Inc. insiders filed 0 open-market purchases and 2 sales; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Neurogene Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 1 insider, $340.0K in total
- Insiders trading
- 1
- Net value
- −$340.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Neurogene Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO | 84,040 | Jul 7, 2026 | 7 |
| Woods Keith | Director | – | Jun 16, 2026 | 4 |
| Shafer Christina | Chief Commercial Officer | – | May 7, 2026 | 1 |
| McMinn Rachel | Chief Executive Officer | 1,344,307 | Mar 30, 2026 | 2 |
| Jordan Julie | Chief Medical Officer | 12,472 | Mar 30, 2026 | 2 |
| Cobb Stuart | Chief Scientific Officer | 30,497 | Mar 17, 2026 | 2 |
| Baffi Robert | Director | – | Feb 24, 2026 | 1 |
| Palekar Rohan | Director | – | Feb 24, 2026 | 1 |
| Noonberg Sarah B. | Director | – | Feb 24, 2026 | 1 |
| Freedland Cory S. | Director | – | Feb 24, 2026 | 1 |
| Woods Robert Keith | Director | – | Jun 13, 2025 | 0 |
| Akkaraju Srinivas | 10% Owner | 1,717,127Indirect | Nov 27, 2024 | 0 |
| Samsara BioCapital, L.P. | 10% Owner | 1,717,127Indirect | Nov 27, 2024 | 0 |
| Samsara BioCapital GP, LLC | 10% Owner | 1,717,127Indirect | Nov 27, 2024 | 0 |
| Baker Julian | Director, Other: Former 10% Owner | 1,658,190Indirect | Dec 20, 2023 | 0 |
| Baker Felix | Director, Other: Former 10% Owner | 1,658,190Indirect | Dec 20, 2023 | 0 |
| Baker Bros. Advisors LP | Director, Other: Former 10% Owner | 1,658,190Indirect | Dec 20, 2023 | 0 |
| Baker Brothers Life Sciences LP | Director, Other: Former 10% Owner | 1,658,190Indirect | Dec 20, 2023 | 0 |
| 667, L.P. | Director, Other: Former 10% Owner | 1,658,190Indirect | Dec 20, 2023 | 0 |
| Baker Bros. Advisors (GP) LLC | Director, Other: Former 10% Owner | 1,658,190Indirect | Dec 20, 2023 | 0 |
| Smith Sean Michael | Interim CFO, Prin Acct Off | 21,637 | Aug 14, 2023 | 0 |
| Simpson Todd E | Director | – | Jun 9, 2023 | 0 |
| Babler Martin | Director | – | Jun 9, 2023 | 0 |
| Lavelle Erin | Director | – | Jun 9, 2023 | 0 |
| Patel Priti | Other: Former Chief Medical Officer | 37,313 | Apr 4, 2023 | 0 |
| Drachman Jonathan G | President and CEO | 25,000Indirect | Aug 4, 2022 | 0 |
| Walkey Carl | Senior Vice President | – | Aug 4, 2022 | 0 |
| Cochener Donna | General Counsel, SVP Legal | – | Aug 4, 2022 | 0 |
| Ho Robert | Chief Financial Officer | – | Feb 2, 2022 | 0 |
| Vance Holly | General Counsel | – | Aug 5, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)9:08 PM ET | Jul 6-7 | 1 day | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $36.12 | −$173.4K | −5.4%84.0K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)6:42 PM ET | Jul 1-2 | 1 day | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $34.71 | −$166.6K | −5.1%88.8K after | 3 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Cvijic Christine MikailPresident and CFO | SSale | −9.60K | $31.26 | −$300.0K | −9.3%93.6K after | 2 lots10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Jordan JulieChief Medical Officer | SSale | −828 | $21.89 | −$18.1K | −6.2%12.5K after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | McMinn RachelChief Executive Officer | SSale | −3.35K | $22.07 | −$74.0K | −0.2%1.34M after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −2.56K | $21.62 | −$55.3K | −2.4%103.2K after | 10b5-1 |
| Mar 17, 2026 (view filing) | Mar 13 | 4 days | Cobb StuartChief Scientific Officer | SSale | −6.80K | $20.81 | −$141.4K | −18.2%30.5K after | 3 lots10b5-1 |
| Mar 17, 2026 (view filing) | Mar 13 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.04K | $20.81 | −$84.2K | −3.7%105.8K after | 3 lots10b5-1 |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $25.11 | −$120.5K | −4.2%109.8K after | 10b5-1 |
| May 15, 2025 (view filing) | May 14 | 1 day | Cobb StuartChief Scientific Officer | SSale | −6.80K | $15.15 | −$103.0K | −24.6%20.8K after | 10b5-1 |
| Mar 17, 2025 (view filing) | Mar 13 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.50K | $16.94 | −$76.2K | −5.9%72.3K after | 10b5-1 |
| Nov 27, 2024 (view filing)4:39 PM ET | Nov 26 | 1 day | Akkaraju Srinivas and 2 others10% Owner | PPurchase | +48.8K | $25.83 | +$1.26M | +2.9%1.72M after | 4 lots |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Cvijic Christine MikailPresident and CFO | PPurchase | +24.0K | $20.48 | +$491.5K | +45.4%76.8K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | McMinn RachelChief Executive Officer | PPurchase | +47.5K | $20.40 | +$969.0K | +3.8%1.30M after | |
| Aug 17, 2023 (view filing)5:08 PM ET | Aug 15-17 | 2 days | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +2.29M | $0.6404 | +$1.46M | +68.7%5.61M after | 12 lots |
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Smith Sean MichaelInterim CFO, Prin Acct Off | SSale | −1.32K | $0.62 | −$820.26 | −5.8%21.6K after | |
| Apr 4, 2023 (view filing) | Apr 3 | 1 day | Patel PritiOther: Former Chief Medical Officer | SSale | −3.77K | $0.69 | −$2.60K | −9.2%37.3K after | |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | Smith Sean MichaelPrincipal Accounting Officer | SSale | −3.32K | $0.60 | −$1.99K | −17.2%16.0K after | |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | Patel PritiChief Medical Officer | SSale | −14.4K | $0.60 | −$8.63K | −31.6%31.1K after | |
| Aug 12, 2022 (view filing) | Aug 10 | 2 days | Smith Sean MichaelPrincipal Accounting Officer | SSale | −1.66K | $0.99 | −$1.64K | −19.6%6.78K after | |
| May 3, 2022 (view filing) | May 2 | 1 day | Patel PritiChief Medical Officer | SSale | −5.54K | $1.22 | −$6.76K | −46.2%6.46K after | |
| Aug 26, 2021 (view filing) | Aug 24 | 2 days | Drachman Jonathan GPresident and CEO | PPurchase | +100.0K | $6.11 | +$611.0K | +4.4%2.35M after | |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Drachman Jonathan GPresident and CEO | PPurchase | +50.0K | $6.45 | +$322.5K | New position25.0K after | 2 lots |